SatiMed’s team of researchers and pharmacologists built a unique competence to retrieve and use the therapeutic values of natural herbal remedies derived from industrial hemp plants. “There is a fast growing demand for hemp-based products, ranging from dietary supplements to cosmetics, and a vast unexplored potential waiting to be unlocked by scientists, consumers, and product development companies. We are excited about the launch of our operations in the USA and the introduction of Sativera products in the marketplace,” said Dr. Jokubas Ziburkus, President and Chief Science Officer of SatiMed.
In addition, the company, together with its affiliate European partner, SatiMed UAB, just announced the launch of an 18 month pre-clinical in-vitro and in-vivo study program using its patent-pending topical formulations to prove their therapeutic properties and to advance the clinical trials. “As a scientist, I am most excited about our recent pre-clinical studies agreement, which will cover in-vitro and in-vivo trials in deep tissue and atopic skin model systems. The results of these trials will pave the future of our company, leading us to our ultimate goal of producing stable, pure, phytocannabinoid-based pharmaceuticals and medical devices,” added Dr. Ziburkus.
Sativera products will be available at www.sativera.com and through various sales channels, regional distributors and e-commerce platforms.
About SatiMed, Inc.
SatiMed, Inc., delivers the highest quality industrial hemp extract and phytocannabinoid-based products. The company’s European affiliate is a licensed cultivator of industrial hemp in Lithuania, which is famous for its pristine open-air conditions, situated above one of the cleanest aquifers in the world. SatiMed owns patent-pending formulations and production know-how, and conforms to the highest GMP standards. SatiMed has developed partnerships with leading scientists in the USA and the EU to determine a biochemical spectrum of distinct industrial hemp constituents, and study biological and translational functions of phytocannabinoids in health and disease.
Food and Drug Administration Disclosure
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Forward-Looking Disclaimer
This release may contain forward-looking statements that involve risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. These statements are only as of the date of this document and we do not undertake to publicly update or revise these forward-looking statements.
Legal Disclosure
SatiMed, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. Cannabidiol and other cannabinoids are natural constituents of hemp oil.
Contact Information
Jokubas Ziburkus, PhD, President and Chief Science Officer
Email
Website: www.satimed.us
Phone: (832) 930 7284
SOURCE SatiMed, Inc.
Related Links
Read more at: http://www.prnewswire.com/news-releases/satimed-inc-launches-its-usa-operations-introduces-hemp-extract-based-patent-pending-cosmetic-products-and-commences-pre-clinical-studies-300266588.html
